Biomarkers to diagnose ventricular dysfunction in childhood cancer survivors: a systematic review
- Leerink, J.M.
- Verkleij, S.J.
- Feijen, E.A.M.
- Mavinkurve-Groothuis, A.M.C.
- Pourier, M.S.
- Ylanen, K.
- Tissing, W.J.E.
- Louwerens, M.
- Heuvel, M.M. van den
- Dulmen-den Broeder, E. van
- Vries, A.C.H. de
- Ronckers, C.M.
- Pal, H.J.H. van der
- Kapusta, L.
- Loonen, J.
- Bellersen, L.
- Pinto, Y.M.
- Kremer, L.C.M.
- Kok, W.E.M.
DOIAbstract
Objective To systematically review the literature and assess the diagnostic value of biomarkers in detection of late-onset left ventricular (LV) dysfunction in childhood cancer survivors (CCS) treated with anthracyclines. Methods We systematically searched the literature for studies that evaluated the use of biomarkers for detection of LV dysfunction in CCS treated with anthracyclines more than 1 year since childhood cancer diagnosis. LV dysfunction definitions were accepted as an ejection fraction <50% or <55% and/or a fractional shortening <28%, Results Of 1362 original studies screened, eight heterogeneous studies evaluating four different biomarkers in mostly asymptomatic CCS were included. In four studies, an abnormal N-terminal pro-B-...
Add to ORKG